This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
List view / Grid view
Filter the results
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
A single change to the structure of bacterial ribosomes prevents macrolide antibiotics from binding and killing the bacteria, according to a study.
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Scientists have identified a potential alternative to antibiotics, a nutrient named taurine that helps the microbiome kill invading bacteria.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
A new study shows that methacycline, a commonly used antibiotic, can reduce the neurological damage caused by Zika virus infections in mice.
An inexpensive molecule showed efficacy against antibiotic-resistant Neisseria gonorrhoeae and Neisseria meningitidis in an animal model.
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
A team has developed 10 new versions of the antibiotic gramicidin A, which they say should be safe for use in pills or injections.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.